益肾健骨方药联合99Tc-MDP治疗肾虚精亏型骨质疏松临床观察

Clinical Observation of Yishen Jiangu Prescription Combined with 99Tc-MDP for Osteoporosis of Kidney Asthenia and Essence Deficiency Type

目的:观察益肾健骨方药联合99Tc-MDP治疗肾虚血瘀型骨质疏松的临床疗效。方法:将86例患者随机分为2组各43例,治疗组静脉滴注99Tc-MDP,同时配合口服益肾健骨方中药颗粒治疗;对照组单纯静脉滴注99Tc-MDP治疗。2组均治疗10~15天(男10天,女15天)为1疗程,每年治疗3疗程。观察比较2组治疗前后骨密度变化情况、临床疗效及不良反应发生情况。结果:治疗后,2组L_1~L_4骨密度、股骨颈骨密度情况分别与治疗前比较,差异均有统计学意义(P<0.05);治疗后,2组L_1~L_4骨密度、股骨颈骨密度组间比较,差异均有统计学意义(P<0.05)。2组临床疗效比较,差异无统计学意义(P>0.05),半年后随访治疗组仅1例复发,对照组2例,其余均疗效巩固。观察过程中2组均无不良反应发生。结论:益肾健骨方药联合99Tc-MDP能改善骨质疏松患者骨密度,且优于单纯使用99Tc-MDP治疗。

Objective： To observe the clinical effect of Yishen Jiangu prescription combined with 99Tc-MDP for osteoporosis of kidney asthenia and blood stasis type. Methods： Divided 86 cases of patients randomly into two groups, 43 cases in each group. The treatment group received intravenous drip of 99Tc-MDP combined with oral administration of granules of Yishen Jiangu prescription, while the control group simply received intravenous drip of 99Tc-MDP. Both groups received treatment for 10-15 days （10 days for men, 15 days for women） as one course, 3 courses for each year. Observed and compared changes of bone mineral density（BMD）, the clinical effect and adverse reaction between the both groups before and after treatment. Results： After treatment, compared L1-L4 BMD and femoral neck BMD of both groups respectively to those before treatment, differences were significant（P 〈0.05）. After treatment, compared L1-L4 BMD and femoral neck BMD of both groups, differences were significant（P〈 0.05）. Compared the clinical effect of both groups, there was no significance in difference（P〉 0.05）. After half a year of follow-up, there was one case of recurrence in the treatment group and two cases of recurrence in the control group, while the curative effect was consolidated in other cases. There was no incidence of adverse reaction in both groups during the observation. Conclusion： The therapy of Yishen Jiangu prescription combined with 99Tc-MDP can effectively improve BMD of patients with osteoporosis, and it is superior to simple 99Tc-MDP treatment.